Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7370-7379

  Di Fabio, Romano ^a   St Denis, Yves ^a   Sabbatini, Fabio M ^a   Andreotti, Daniele ^a   Arban, Roberto ^a   Bernasconi, Giovanni ^a   Braggio, Simone ^a   Blaney, Frank E ^b   Capelli, Anna M ^a   Castiglioni, Emiliano ^a   Di Modugno, Enza ^a   Donati, Daniele ^a   Fazzolari, Elettra ^a   Ratti, Emiliangelo ^a   Feriani, Aldo ^a   Contini, Stefania ^a   Gentile, Gabriella ^a   Ghirlanda, Damiano ^a   Provera, Stefano ^a   Marchioro, Carla ^a   Roberts, Karen L ^a   Mingardi, Anna ^a   Mattioli, Mario ^a   Nalin, Arnaldo ^a   Pavone, Francesca ^a   Spada, Simone ^a   Trist, David G ^a   Worby, Angela ^c   more..

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Molecular Discovery Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [6 METHYL 1 [2 METHYL 4 (METHYLOXY)PHENYL] 2,3 DIHYDRO 1H PYRROLO[2,3 B]PYRIDIN 4 YL] 1H PYRAZOL 3 YL] 2 IMIDAZOLIDINONE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 [3 (1,1 DIOXIDO 1,2,5 THIADIAZOLIDIN 2 YL) 1H PYRAZOL 1 YL] 6 METHYL 1 [(2 METHYL 4 METHYLOXY)PHENYL] 2,3 DIHYDRO 1H PYRROLO[2,3 B]PYRIDINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ANTAGONIST; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HYDROGEN BOND; HYDROPHILICITY; MALE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; FORELIMB; GERBILLINAE; HUMANS; MALE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PSYCHOLOGICAL TESTS; PYRIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STEREOISOMERISM; ULTRASONICS; VOCALIZATION, ANIMAL;

EID: 57349191054     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800744m     Document Type: Article

References (22)

1. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secrection of cortocotropin and beta-endorphine. Science 1981, 213, 1394-1397.
2. Owen, M. J.; Nemeroff, C. B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Res. 1991, 43, 425-473.
3. De Souza, E. B. Corticoptopin-releasing factor receptors: physiology, pharmacology, biochemitry and role in central nervous system and immune disorders. Psychoneuroendocrinology 1995, 20, 789-819.
4. Rivier, C.; Vale, W. Modulation of stress-induced ACTH release by cortocotropin-releasing factor, catecholamines and vasopressin. Nature 1983, 305, 325-327.
5. Holsboer, F. The rational for corticotropin-releasing hormone receptors (CRH-R) antagonists to treat depression and anxiety. J. Psychiatric. Res. 1999, 33, 181-214.
6. Schulz, D. W.; Mansbach, R. S.; Sprouse, J.; Braselton, J. P.; Collins, J.; Corman, M.; Dunaiskis, A.; Faraci, S.; Schmidt, A. W.; Seeger, T.; Seymour, P.; Tingley, F. D.; Winston, E. N.; Chen, Y. L.; Heym, J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10477-10482.
7. Mansbach, R. S.; Brooks, E. N.; Chen, Y. L. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol. 1997, 323, 21-26.
8. Millan, M. J.; Brocco, M.; Gobert, A.; Dorey, G.; Casara, P.; Dekeyne, A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 2001, 25, 585-600.
9. Zobel, A. W.; Nickel, T.; Kunzel, H. E.; Ackl, N.; Sonntag, A.; Ising, M.; Holsboer, F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist NBI30775 in major depression: the first 20 patients treated. J. Psychiatr. Res. 2000, 34, 171-181.
10. Habib, K. E.; Weld, K. P.; Rice, K. C.; Pushkas, J.; Champoux, M.; Listwak, S.; Webster, E. L.; Atkinson, A. J.; Schulkin, J.; Contoreggi, C.; Chrousos, G. P.; McCann, S. M.; Suomi, S. J.; Higley, J. D.; Gold, P. W. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6079-6084.
11. Li, Y. W.; Hill, G.; Wong, H.; Kelly, N.; Ward, K.; Pierdomenico, M.; Ren, S.; Gilligan, P.; Grossman, S.; Trainor, G.; Taub, R.; McElroy, J.; Zazcek, R. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J. Pharmacol. Exp. Ther. 2003, 305, 86-96.
12. Heinrichs, S. C.; De Souza, E. B.; Schulteis, G.; Lapsansky, J. L.; Grigoriadis, D. E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 2002, 27, 194-202.
13. Di Fabio, R.; Arban, R.; Bernasconi, G.; Braggio, S.; Blaney, F. E.; Capelli, A. M.; Castiglioni, E.; Donati, D.; Fazzolari, F.; Ratti, E.; Feriani, F.; Contini, S.; Gentile, G.; Ghirlanda, D.; Sabbatini, F. M.; Andreotti, D.; Spada, S.; Marchioro, C.; Worby, A.; St-Denis, Y. J. Med. Chem. 2008, in press.
14. Chen, C. Recent advances in small molecule antagonists of the corticotropin-releasing factor of type-1 receptor. Focus on Pharmacology and Pharmacokinetics. Curr. Med. Chem 2006, 13, 1261-1282, and references herein enclosed.
15. All pharmacokinetic experiments were performed with the compound 3 as free base. Compound 3 was administered to rat and marmoset as bolus in a solution of N,N-dimethylacetamide/EtOH/PEG400/H2O1:1:6:2. Both species were dosed orally using a 0.5% methocel suspension,
16. Gully, D.; Geslin, M.; Serva, L.; Fontaine, E.; Roger, P.; Lair, C.; Darre, V.; Marcy, C.; Rouby, P. E.; Simiand, J.; Guitard, J.; Gout, G.; Steinberg, R.; Rodier, D.; Griebel, G.; Soubrie, P.; Pascal, M.; Pruss, R.; Scatton, B.; Maffrand, J. P.; Le Fur, G. 4-(2-Chloro-4-methoxy-5-methylphenyl) -N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl] 5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): A potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther 2002, 301, 322-332.
17. Chaki, S.; Nakazato, A.; Kennis, L.; Nakamura, M.; Mackie, C.; Sugiura, M. Anxiolytic andantidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol. 2004, 485, 145-158.
18. Gardner, C. R. Distress vocalization in rat pups a simple screening method for anxiolytic drugs. J. Pharmacol. Methods 1985, 14, 181-187.
19. Kehne, J. H.; Coverdale, S.; McCloskey, T. C.; Hoffman, D. C.; Cassella, J. V. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 2000, 39, 1357-1367.
20. Costall, B.; Domeney, A. M.; Gerrard, P. A.; Naylor, R. J. A primate model for assessment of anxiolytic drug action. Br. J. Pharmacol. 1988, 95, 475P.
21. Lipp, H. P. Aggression and flight behavior of the marmoset monkey (Callithrix jacchus), an ethogram for brain stimulation studies. Brain Behav. Biol. 1978, 15, 241-259.
22. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.